Spero Therapeutics, Inc. (SPRO): Total Liabilities
$9.90M
As of 2025-12-31
$8.56M
As of 2026-06-30
-41.3%
3-year compound annual growth
-14.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.90M | -84.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $64.42M | -14.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $75.50M | +54.5% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $48.87M | -41.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $82.78M | +286.6% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $21.41M | -32.1% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $31.53M | +139.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $13.15M | +54.3% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $8.52M | +15.0% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $7.41M | n/a | 2018-04-02, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗